Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the... see more

TSX:EDT - Post Discussion

Spectral Medical Inc > Questions for the company.
View:
Post by oilandgasman on Nov 30, 2021 11:01am

Questions for the company.

We could work together on asking relevant questions, who knows if or when the chance comes around again?

I'm very curious about the delay in the pump trial and if DeVita actually has a roll.
I'd also like a clear answer on what sets this pump apart from the competitors in the pump market place, besides the pricing.

It might be good to post the questions here..seeing what thses guys will talk about and what they won't it could be helpful.
Comment by oilandgasman on Nov 30, 2021 1:08pm
What's the status of finding a distribution partner for Sami and/or Dimi?   If vaccine mandates are driving staffing shortages at dialysis clinics, then why not conduct the Dimi trial in only red states that don't have mandates in place?   Is Davita going to be one or more of the Dimi trial sites?   What degree of confidence do you have that Dimi trial will ...more  
Comment by hmmmmmmmm on Nov 30, 2021 5:47pm
I agree, this is a fair question- as the subject has gone quiet in updates- What's the status of finding a distribution partner for Sami? I'd also like to understand how in late Semptember CEO Chris Seto was stating that their Tigris Trial would be very close to reaching 60% enrollment by the end of the year.  From the last numbers released by the company it looks like they'll ...more  
Comment by oilandgasman on Dec 01, 2021 10:29am
When did Seto say 60 was doable?
Comment by Domino55 on Nov 30, 2021 7:14pm
You missed the obvious elephant in the room;" with all the developments of the past 12 months can you elaborate on why the shares trade at 23 cents Cdn?"
Comment by mercedesman on Nov 30, 2021 9:00pm
"We don't comment on the share price" "But the company has lost 2/3rds of it's Market cap in the pst three months?" "We don't comment on the market cap" "What does the Board know about who is behind the selling?" " No idea...could be a rogue hedge fund, or maybe someone died and the executors are having an estate sale " ...more  
Comment by hmmmmmmmm on Nov 30, 2021 10:57pm
When a CEO misses a short term enrollment projection by 10X, you're rightly going to sell off and it reflected in the share price. When the start of the DIMI human factor trial quietly falls 6 months behind, you're going to see it reflected in selling and share price. They don't need to explain the share price. They need to explain to investors what they are doing, and NOT doing.
Comment by mercedesman on Nov 30, 2021 11:07pm
When APPLE does a financing and misses their Qtr ( eg top line revenue or units sold)  their market Cap does not go down by 2/3rds, or in their case, $1.8 trillion.  MM 
Comment by Domino55 on Dec 01, 2021 10:15am
Hm. I disagree,  When your FDA approvals are valued at 5 cents per, your late stage PMX confirmatory trial at NOTHING, the share price down 65% in 6 months and down 50% YoY you need to explain that to your shareholders.  We are owed an explanation of how 12 months of development has gotten the SP to where it is.
Comment by mercedesman on Dec 01, 2021 10:54am
Another gold star Dom If the underlying assets don't change And any given stock's value (presumably) is fundamentally represented by all future cash flows (for at least the next 20 years) discounted to present day Should a delay of 6 -9 months (of the start of revenues) really have a material impact (e.g 2/3 loss of MC) on the value of said given stock? Unless the value is not truly ...more  
Comment by Domino55 on Dec 01, 2021 11:43am
MM ; Yes it seems odd to me that some think asking questions about the share price is out of bounds. it is down roughly 60% since the leadership transition, amidst some extremely positive developments. It is the number 1 question in play.
Comment by hmmmmmmmm on Dec 01, 2021 1:37pm
I'm not against asking questions about the SP, but I can't pretend that everything is rosy and there's no real questions on what's dragging out testing. Spectral is a company that is shepherding other company's inventions (Toray= PMX, Infomed= SAMI/DIMI) through FDA testing in order to sell them in the US.  As of Spectral's Nov. 12 update  The Tigris trial (in ...more  
Comment by oilandgasman on Dec 01, 2021 10:27am
I can say 100% they know where every share is...I know because i've interacted with somone in the company and he commented on my count...I was actually suprised.
Comment by oilandgasman on Dec 01, 2021 12:58pm
12:40:35 O 0.23 -0.01 500 1 Anonymous 14 ITG K 12:40:35 O 0.23 -0.01 1,000 1 Anonymous 14 ITG K 12:40:35 M 0.235 -0.005 1,000 1 Anonymous 14 ITG    ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities